arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.
Company profile
Ticker
ARQT
Exchange
Website
CEO
Todd Franklin Watanabe
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Arcutis, Inc.
SEC CIK
Corporate docs
IRS number
812974255
ARQT stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
10 Apr 24
8-K
Other Events
4 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
28 Feb 24
8-K
Entry into a Material Definitive Agreement
28 Feb 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 Feb 24
8-K
Departure of Directors or Certain Officers
15 Feb 24
SC TO-I/A
Issuer tender offer statement (amended)
15 Feb 24
Latest ownership filings
4
David Joseph Topper
11 Apr 24
3
David Joseph Topper
11 Apr 24
4
Masaru Matsuda
6 Mar 24
4
Patrick Burnett
6 Mar 24
4
Todd Franklin Watanabe
6 Mar 24
4
Matthew Richard Moore
6 Mar 24
4
Patrick J Heron
6 Mar 24
SC 13D/A
Frazier Life Sciences VIII, L.P.
6 Mar 24
SC 13G/A
JENNISON ASSOCIATES LLC
6 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 108.40 mm | 108.40 mm | 108.40 mm | 108.40 mm | 108.40 mm | 108.40 mm |
Cash burn (monthly) | (no burn) | (no burn) | 12.30 mm | 20.70 mm | 14.66 mm | 21.82 mm |
Cash used (since last report) | n/a | n/a | 84.72 mm | 142.53 mm | 100.97 mm | 150.29 mm |
Cash remaining | n/a | n/a | 23.68 mm | -34.14 mm | 7.42 mm | -41.90 mm |
Runway (months of cash) | n/a | n/a | 1.9 | -1.6 | 0.5 | -1.9 |
Institutional ownership, Q3 2023
80.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 135 |
Opened positions | 16 |
Closed positions | 21 |
Increased positions | 53 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 343.37 bn |
Total shares | 78.36 mm |
Total puts | 496.90 k |
Total calls | 117.90 k |
Total put/call ratio | 4.2 |
Largest owners | Shares | Value |
---|---|---|
Frazier Life Sciences VIII | 8.68 mm | $218.41 mm |
Frazier Life Sciences Management | 8.68 mm | $46.11 bn |
FMR | 8.26 mm | $43.87 bn |
Rubric Capital Management | 5.03 mm | $26.73 bn |
Jennison Associates | 4.43 mm | $23.53 bn |
STT State Street | 4.36 mm | $23.16 bn |
BLK Blackrock | 4.02 mm | $21.35 bn |
Polar Capital | 3.12 mm | $16.56 bn |
Bain Capital Life Sciences Investors | 3.00 mm | $15.93 bn |
Vanguard | 2.88 mm | $15.29 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Apr 24 | David Joseph Topper | Common Stock | Grant | Acquire A | No | No | 0 | 110,000 | 0.00 | 110,000 |
10 Apr 24 | David Joseph Topper | Stock Option Common Stock | Grant | Acquire A | No | No | 12.34 | 310,000 | 3.83 mm | 310,000 |
4 Mar 24 | Masaru Matsuda | Common Stock | Sell | Dispose S | No | Yes | 11.1212 | 3,760 | 41.82 k | 190,424 |
4 Mar 24 | Patrick Burnett | Common Stock | Sell | Dispose S | No | Yes | 11.1212 | 4,782 | 53.18 k | 269,300 |
4 Mar 24 | Matthew Richard Moore | Common Stock | Sell | Dispose S | No | Yes | 11.1212 | 3,468 | 38.57 k | 146,020 |
News
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
12 Apr 24
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $16 Price Target
12 Apr 24
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
11 Mar 24
Arcutis Announces Acceptance Of Late Breaking Abstract In Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented At The American Academy Of Dermatology Annual Meeting
4 Mar 24
Arcutis Prices $150M Public Offering Of 15,789,474 Common Shares At $9.50/Share
29 Feb 24
Press releases
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Apr 24
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
28 Mar 24
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
10 Mar 24
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
9 Mar 24
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Mar 24